000836360 001__ 836360
000836360 005__ 20210129230950.0
000836360 0247_ $$2doi$$a10.2967/jnumed.116.185538
000836360 0247_ $$2ISSN$$a0022-3123
000836360 0247_ $$2ISSN$$a0097-9058
000836360 0247_ $$2ISSN$$a0161-5505
000836360 0247_ $$2ISSN$$a1535-5667
000836360 0247_ $$2ISSN$$a2159-662X
000836360 0247_ $$2WOS$$aWOS:000402572500021
000836360 0247_ $$2altmetric$$aaltmetric:14417421
000836360 0247_ $$2pmid$$apmid:27908968
000836360 037__ $$aFZJ-2017-05481
000836360 041__ $$aEnglish
000836360 082__ $$a610
000836360 1001_ $$0P:(DE-HGF)0$$aDietlein, Felix$$b0$$eCorresponding author
000836360 245__ $$aPSA-Stratified Performance of $^{18}$F- and $^{68}$Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
000836360 260__ $$aNew York, NY$$bSoc.$$c2017
000836360 3367_ $$2DRIVER$$aarticle
000836360 3367_ $$2DataCite$$aOutput Types/Journal article
000836360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1501498400_31605
000836360 3367_ $$2BibTeX$$aARTICLE
000836360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000836360 3367_ $$00$$2EndNote$$aJournal Article
000836360 520__ $$aSeveral studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with 18F offers numerous advantages, including improved image resolution, longer half-life, and increased production yields. The aim of this study was to assess the PSA-stratified performance of the 18F-labeled PSMA tracer 18F-DCFPyL and the 68Ga-labeled reference 68Ga-PSMA-HBED-CC. Methods: We examined 191 consecutive patients with biochemical recurrence according to standard acquisition protocols using 18F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or 68Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after injection). We determined PSA-stratified sensitivity rates for both tracers and corrected our calculations for Gleason scores using iterative matched-pair analyses. As an orthogonal validation, we directly compared tracer distribution patterns in a separate cohort of 25 patients, sequentially examined with both tracers. Results: After prostatectomy (n = 106), the sensitivity of both tracers was significantly associated with absolute PSA levels (P = 4.3 × 10−3). Sensitivity increased abruptly, when PSA values exceeded 0.5 μg/L (P = 2.4 × 10−5). For a PSA less than 3.5 μg/L, most relapses were diagnosed at a still limited stage (P = 3.4 × 10−6). For a PSA of 0.5–3.5 μg/L, PSA-stratified sensitivity was 88% (15/17) for 18F-DCFPyL and 66% (23/35) for 68Ga-PSMA-HBED-CC. This significant difference was preserved in the Gleason-matched-pair analysis. Outside of this range, sensitivity was comparably low (PSA < 0.5 μg/L) or high (PSA > 3.5 μg/L). After radiotherapy (n = 85), tracer sensitivity was largely PSA-independent. In the 25 patients examined with both tracers, distribution patterns of 18F-DCFPyL and 68Ga-PSMA-HBED-CC were strongly comparable (P = 2.71 × 10−8). However, in 36% of the PSMA-positive patients we detected additional lesions on the 18F-DCFPyL scan (P = 3.7 × 10−2). Conclusion: Our data suggest that 18F-DCFPyL is noninferior to 68Ga-PSMA-HBED-CC, while offering the advantages of 18F labeling. Our results indicate that imaging with 18F-DCFPyL may even exhibit improved sensitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels. Although the standard acquisition protocols, used for 18F-DCFPyL and 68Ga-PSMA-HBED-CC in this study, stipulate different activity doses and tracer uptake times after injection, our findings provide a promising rationale for validation of 18F-DCFPyL in future prospective trials.
000836360 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000836360 588__ $$aDataset connected to CrossRef
000836360 7001_ $$0P:(DE-HGF)0$$aKobe, Carsten$$b1
000836360 7001_ $$0P:(DE-HGF)0$$aNeubauer, Stephan$$b2
000836360 7001_ $$0P:(DE-HGF)0$$aStockter, Simone$$b3
000836360 7001_ $$0P:(DE-HGF)0$$aFischer, Thomas$$b4
000836360 7001_ $$0P:(DE-HGF)0$$aSchomäcker, Klaus$$b5
000836360 7001_ $$0P:(DE-HGF)0$$aHeidenreich, Axel$$b6
000836360 7001_ $$0P:(DE-HGF)0$$aZlatopolskiy, Boris D.$$b7
000836360 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b8
000836360 7001_ $$0P:(DE-HGF)0$$aDrzezga, Alexander$$b9
000836360 7001_ $$0P:(DE-HGF)0$$aDietlein, Markus$$b10
000836360 7001_ $$0P:(DE-HGF)0$$aSchmidt, M.$$b11
000836360 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.116.185538$$gVol. 58, no. 6, p. 947 - 952$$n6$$p947 - 952$$tJournal of nuclear medicine$$v58$$x2159-662X$$y2017
000836360 909CO $$ooai:juser.fz-juelich.de:836360$$pVDB
000836360 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b8$$kFZJ
000836360 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000836360 9141_ $$y2017
000836360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2015
000836360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000836360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000836360 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000836360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000836360 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000836360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000836360 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000836360 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000836360 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000836360 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000836360 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2015
000836360 920__ $$lyes
000836360 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000836360 980__ $$ajournal
000836360 980__ $$aVDB
000836360 980__ $$aI:(DE-Juel1)INM-5-20090406
000836360 980__ $$aUNRESTRICTED